The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
AbbVie Inc (ABBV) is a leading drug manufacturers - general business with stocks listed in the US. It closed the previous market day at US$205.2. During the previous open market day, the price has varied from a low of USD201.8 to a high of USD206.005. AbbVie is listed on the NYSE. All prices are listed in US Dollars.
How to buy shares in AbbVie
- Compare share trading platforms. To buy shares in a company listed in the US from Australia you'll need to find a trading platform that offers access to US stock markets. Look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, which will typically include your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for AbbVie. Find the share by name or ticker symbol: ABBV. Research its history to confirm it's a solid investment that matches your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until AbbVie reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying using consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$205.2, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of AbbVie, depending on your broker.
- Check in on your investment. Congratulations, you own a part of AbbVie. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights.
Compare trading platforms to buy AbbVie shares
Compare other products
We currently don't have that product, but here are others to consider:
How we picked theseFinder Score for share trading platforms
We've scored over 30 share trading platforms assessing them for their core features, fees, customer experience and accessibility. Our experts give each platform a score out of 10.
AbbVie shares at a glance
Information last updated 2026-03-21.
| 52-week range | US$159.0544 - US$241.1178 |
|---|---|
| 50-day moving average | US$223.1194 |
| 200-day moving average | US$215.249 |
| Target price | US$249.1379 |
| PE ratio | 86.1639 |
| Dividend yield | US$6.65 (3.22%) |
| Earnings per share (TTM) | US$2.38 |
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
AbbVie price performance over time
Historical closes compared with the last close of $205.2
| 1 week (2026-03-18) | -1.51% |
|---|---|
| 1 month (2026-02-25) | -9.57% |
| 3 months (2025-12-26) | -10.77% |
| 6 months (2025-09-26) | -6.99% |
| 1 year (2025-03-26) | 1.94% |
|---|---|
| 2 years (2024-03-26) | 14.52% |
| 3 years (2023-03-24) | 29.86% |
| 5 years (2021-03-25) | 97.54% |
Is it a good time to buy AbbVie stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Is it worth buying AbbVie stock?
Valuing AbbVie stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AbbVie's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
AbbVie's P/E ratio
AbbVie's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 86x. In other words, AbbVie shares trade at around 86x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
AbbVie's PEG ratio
AbbVie's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.4888. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into AbbVie's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
AbbVie's EBITDA
AbbVie's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$29.3 billion (£22 billion).
The EBITDA is a measure of a AbbVie's overall financial performance and is widely used to measure stock profitability.
AbbVie share price volatility
Over the last 12 months, AbbVie's shares have ranged in value from as little as US$159.0544 up to US$241.1178. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NYSE average) beta is 1, while AbbVie's is 0.334. This would suggest that AbbVie's shares are less volatile than average (for this exchange).
AbbVie financials
| Revenue TTM | US$61.2 billion |
|---|---|
| Operating margin TTM | 34.11% |
| Gross profit TTM | US$43.8 billion |
| Return on assets TTM | 9.81% |
| Return on equity TTM | 62.25% |
| Profit margin | 6.91% |
| Book value | -1.85 |
| Market capitalisation | US$362.6 billion |
| EBITDA | US$29.3 billion |
TTM: trailing 12 months
AbbVie share dividends
Dividend payout ratio: 67.4% of net profits
Recently AbbVie has paid out, on average, around 67.4% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.37% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), AbbVie shareholders could enjoy a 3.37% return on their shares, in the form of dividend payments. In AbbVie's case, that would currently equate to about $6.65 per share.
AbbVie's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
AbbVie's most recent dividend payout was on 14 May 2026. The latest dividend was paid out to all shareholders who bought their shares by 14 April 2026 (the "ex-dividend date").
AbbVie's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like AbbVie.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
AbbVie's total ESG risk score
Total ESG risk: 34.86
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and AbbVie's overall score of 34.86 (as at 12/31/2018) is pretty weak – landing it in it in the 66th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like AbbVie is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
AbbVie's environmental score
Environmental score: 4.96/100
AbbVie's environmental score of 4.96 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that AbbVie is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
AbbVie's social score
Social score: 22.65/100
AbbVie's social score of 22.65 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that AbbVie is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
AbbVie's governance score
Governance score: 16.25/100
AbbVie's governance score puts it squarely in the 7th percentile of companies rated in the same sector. That could suggest that AbbVie is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
AbbVie's controversy score
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. AbbVie scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that AbbVie hasn't always managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
AbbVie Inc was last rated for ESG on: 2019-01-01.
| Total ESG score | 34.86 |
|---|---|
| Total ESG percentile | 65.78 |
| Environmental score | 4.96 |
| Environmental score percentile | 7 |
| Social score | 22.65 |
| Social score percentile | 7 |
| Governance score | 16.25 |
| Governance score percentile | 7 |
| Level of controversy | 3 |
AbbVie overview
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Frequently asked questions
Sources
More resources on Finder
Ask a question
More guides on Finder
-
Betashares Direct review
Pay zero brokerage when you invest in ASX ETFs using Betashares Direct.
-
Best performing stocks on the ASX
Top gainers included EQ Resources, Viva Energy Group and Elsight.
-
Sharesies review
Here's a detailed review of micro-investing app Sharesies plus its key features and pros and cons.
-
ASX lithium stocks
Lithium is a precious metal with increasing demand. Here’s what you should know before you invest.
-
What are the best AI stocks on the ASX in 2026? Stocks and ETFs to watch
Here's what investors should know before adding AI stocks to their portfolios.
-
Vanguard Personal Investor review
We took a look at the features and fees of the latest share trading platform.
-
How to invest in Nasdaq from Australia
Find out how you can invest in Nasdaq and compare a range of leading brokers that let you invest in US stocks cheaply and quickly.
-
How to invest in index funds in Australia
Index funds are a hot topic right now, but how do you actually invest in them?
-
Stake review: A trading platform for AU and US stocks
Stake is a trading platform for Australians who want value for money when trading. Gain access to one of the cheapest CHESS-sponsored and US trading platforms in Australia, and $3 brokerage in the US.
-
Totality (formerly Saxo) Australia review: Share trading platform
Totality allows you to trade over 60,000 instruments on 50 global stock exchanges and provides lower commissions for active traders.